Abstract
The Prostate Cancer Prevention Trial included approximately 18 000 men aged 55-70 years with a prostate-specific antigen level of <3.0 ng/mL randomized to receive Proscar (finasteride) or placebo. The overall reduction in prostate cancer risk was about 25% considering all biopsies and about 10% considering “for cause” biopsies. The analysis presented in the study by Kaplan et al. is based on an adjustment for the decrease in the size of the prostate resulting from finasteride use and identified about a 50% reduction for Gleason score 6 and a 20% reduction for Gleason score 7 cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
